Lycia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Lycia Therapeutics's estimated annual revenue is currently $3.6M per year.
- Lycia Therapeutics's estimated revenue per employee is $77,500
- Lycia Therapeutics's total funding is $120M.
Employee Data
- Lycia Therapeutics has 46 Employees.
- Lycia Therapeutics grew their employee count by 35% last year.
Lycia Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Head Chemistry | Reveal Email/Phone |
3 | VP, Nonclinical Development | Reveal Email/Phone |
4 | VP, Nonclinical Development | Reveal Email/Phone |
5 | VP, Finance | Reveal Email/Phone |
6 | Head Nonclinical Development | Reveal Email/Phone |
7 | VP, Intellectual Property | Reveal Email/Phone |
8 | Head Translational Medicine/Early Development | Reveal Email/Phone |
9 | Chief Business Officer | Reveal Email/Phone |
10 | Executive Director - Head Biologics | Reveal Email/Phone |
Lycia Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Lycia Therapeutics?
We are building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
keywords:N/A
$120M
Total Funding
46
Number of Employees
$3.6M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lycia Therapeutics News
... JW Pharmaceutical; Kangpu Biopharmaceuticals; Kymera Therapeutics; Lycia Therapeutics; Macroceutics (Hotspot Therapeutics); Merck & Co...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.1M | 46 | -32% | N/A |
#2 | $7.1M | 46 | 2% | N/A |
#3 | $9M | 46 | 31% | N/A |
#4 | $10.2M | 47 | -4% | N/A |
#5 | $35M | 47 | 9% | N/A |